| Jul 22 |
Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy
|
| Jul 1 |
Vera Therapeutics appoints David Johnson as COO
|
| Jul 1 |
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
|
| Jun 11 |
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
|
| Jun 7 |
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
|
| May 31 |
Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market
|
| May 29 |
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
|
| May 28 |
Vera gains FDA Breakthrough Therapy Designation for atacicept
|
| May 28 |
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
|
| May 25 |
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
|
